NCT04788043View on ClinicalTrials.gov

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 21, 2022

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions
Hodgkin LymphomaClassic Hodgkin LymphomaRelapsed Classical Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
Interventions
DRUG

Magrolimab

45 mg/kg with dose escalation starting at 1 mg/kg IV Infusion

DRUG

Pembrolizumab

200 mg IV infusion

PROCEDURE

PET/CT

Scan

Trial Locations (2)

94304

Stanford University, Stanford

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Stanford University

OTHER